首页> 美国卫生研究院文献>Cancer Science >Epitope Blocking: Positive and Negative Effects on the Biodistribution of 125I‐Labeled Anti‐Tac Disulfide‐stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen
【2h】

Epitope Blocking: Positive and Negative Effects on the Biodistribution of 125I‐Labeled Anti‐Tac Disulfide‐stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen

机译:抗原决定簇阻断:对两种针对循环抗原不同抗原决定簇的抗体的125I标签的抗Tac二硫键稳定的Fv片段的生物分布的正负影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prior in vivo studies using the 125I‐labeled anti‐Tac disulfide‐stabilized variable region fragment (125I‐anti‐Tac dsFv) of monoclonal antibody in the presence of the circulating soluble alpha subunit of the interleukin‐2 receptor (sIL‐2Rα) have shown formation of complexes which interfere with biodistribution. In this study we evaluated the effects of preinjecting HuTac and 7G7/B6, two immunoglobulin Gs (IgGs) that recognize different epitopes of sIL‐2Rα, on the biodistribution of 125I‐anti‐Tac dsFv in mice bearing SP2/Tac tumor xenografts, which produce sIL‐2Rα, or on nude mice injected with 500 ng of sIL‐2Rα. We also evaluated the biodistribution in mice of 125I‐labeled sIL‐2Rα injected alone or with HuTac and 7G7/B6. Injection of either HuTac or 7G7/B6 resulted in complexes with the sIL‐2Rα in serum. Injection of HuTac before 125I‐anti‐Tac dsFv, in SP2/Tac tumor‐bearing mice, resulted in faster clearance of the dsFv from the blood (7.6%ID/g at 30 min), compared to 23.2%ID/g for the no‐antibody control; preinjection of 7G7/B6 prolonged the retention of 125I‐anti‐Tac dsFv to 35.3%ID/g, with more complexes in serum. In mice pre‐injected with 7G7/B6 the concentration of 125I‐anti‐Tac dsFv in tumor was lower (5.2±0.3%ID/g) than in mice preinjected with HuTac (7.9±1.2%ID/g) or in the control group (5.6±0.7%ID/g). In conclusion, while both IgGs formed complexes with sIL‐2Rα and prolonged its retention, preinjection of 7G7/ B6 was detrimental, because the increased circulating sIL‐2Rα still had the epitope recognized by the dsFv available for binding and neutralized the anti‐Tac dsFv upon injection, whereas preinjection of HuTac blocked the epitope.
机译:先前的体内研究使用单克隆抗体的 125 I标记的抗Tac二硫键稳定的可变区片段( 125 I-抗Tac dsFv)白细胞介素2受体(sIL-2Rα)的循环可溶性α亚基显示出会干扰生物分布的复合物的形成。在这项研究中,我们评估了预注射HuTac和7G7 / B6(两个识别sIL-2Rα不同表位的免疫球蛋白Gs(IgG))对小鼠 125 I-anti-Tac dsFv生物分布的影响携带SP2 / Tac肿瘤异种移植物,产生sIL-2Rα,或者在裸鼠中注射500 ngsIL-2Rα。我们还评估了单独或与HuTac和7G7 / B6一起注射的 125 I标记的sIL-2Rα在小鼠中的生物分布。注射HuTac或7G7 / B6会导致血清中与sIL-2Rα形成复合物。与SP2 / Tac荷瘤小鼠相比,在 125 I-anti-Tac dsFv之前注射HuTac可以更快地从血液中清除dsFv(30分钟时为7.6%ID / g)对于无抗体对照,达到23.2%ID / g;预注射7G7 / B6可将 125 I-anti-Tac dsFv的保留时间延长至35.3%ID / g,血清中的复合物更多。在预先注射7G7 / B6的小鼠中,肿瘤中 125 I-anti-Tac dsFv的浓度(5.2±0.3%ID / g)比预先注射过HuTac的小鼠(7.9±1.2%)低ID / g)或对照组(5.6±0.7%ID / g)。总之,尽管两种IgG均与sIL-2Rα形成复合物并延长其保留时间,但预先注射7G7 / B6却是有害的,因为循环中增加的sIL-2Rα仍具有被dsFv识别的表位可用于结合并中和抗Tac dsFv在注射时,HuTac的预注射会阻断表位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号